Seeking men and women whose non-small cell lung cancer (NSCLC) has spread outside the lungs, and has a change in the gene called EGFR (epidermal growth factor receptor) and has not yet been treated for a study of an investigational drug combination.
We are studying whether adding an additional drug to the usual treatment for metastatic non-small cell lung cancer (NSCLC) increases the amount of time before the cancer starts growing again and a different treatment is needed. Half of the participants will receive the investigational drug combination and the other half will receive the usual treatment.
What we're hoping for
We hope that an investigational drug combination will increase the amount of time before the non-small cell lung cancer (NSCLC) returns and a different treatment is needed for people with NSCLC that has spread outside their lungs.
ClinicalTrials.gov Identifier: NCT04181060